Commonwealth of Pennsylvania Public School Empls Retrmt SYS Purchases 5,641 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 15.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 42,016 shares of the medical equipment provider’s stock after purchasing an additional 5,641 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Zimmer Biomet were worth $4,715,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Zimmer Biomet by 19.0% during the first quarter. Vanguard Group Inc. now owns 23,102,761 shares of the medical equipment provider’s stock worth $2,954,843,000 after purchasing an additional 3,695,510 shares during the period. BlackRock Inc. raised its position in shares of Zimmer Biomet by 5.2% during the second quarter. BlackRock Inc. now owns 22,098,606 shares of the medical equipment provider’s stock worth $3,217,557,000 after purchasing an additional 1,094,431 shares during the period. State Street Corp raised its position in shares of Zimmer Biomet by 3.6% during the second quarter. State Street Corp now owns 9,056,896 shares of the medical equipment provider’s stock worth $1,320,827,000 after purchasing an additional 318,082 shares during the period. Geode Capital Management LLC raised its position in Zimmer Biomet by 2.3% in the 2nd quarter. Geode Capital Management LLC now owns 4,413,445 shares of the medical equipment provider’s stock valued at $640,904,000 after buying an additional 98,278 shares during the last quarter. Finally, Morgan Stanley raised its position in Zimmer Biomet by 80.5% in the 4th quarter. Morgan Stanley now owns 3,102,429 shares of the medical equipment provider’s stock valued at $395,560,000 after buying an additional 1,384,068 shares during the last quarter. 87.48% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on ZBH. Evercore ISI lowered Zimmer Biomet from an “outperform” rating to an “inline” rating and lowered their price target for the company from $135.00 to $125.00 in a research report on Thursday, January 4th. Morgan Stanley increased their price target on Zimmer Biomet from $120.00 to $125.00 and gave the company an “equal weight” rating in a research report on Monday, December 4th. Truist Financial increased their price target on Zimmer Biomet from $133.00 to $135.00 and gave the company a “hold” rating in a research report on Friday. StockNews.com raised Zimmer Biomet from a “buy” rating to a “strong-buy” rating in a research report on Friday. Finally, Raymond James increased their price target on Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Two analysts have rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $138.11.

Get Our Latest Report on ZBH

Zimmer Biomet Stock Down 0.2 %

ZBH stock opened at $122.80 on Monday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. The company has a market capitalization of $25.66 billion, a price-to-earnings ratio of 25.11, a PEG ratio of 2.23 and a beta of 1.03. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $149.25. The stock has a fifty day moving average of $121.39 and a 200-day moving average of $117.35.

Zimmer Biomet (NYSE:ZBHGet Free Report) last issued its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. The business had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.88 EPS. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.03 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 31st. Investors of record on Wednesday, December 27th were issued a dividend of $0.24 per share. The ex-dividend date was Tuesday, December 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.78%. Zimmer Biomet’s dividend payout ratio (DPR) is 19.63%.

About Zimmer Biomet

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Featured Stories

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.